Back to Search
Start Over
Allogeneic Stem Cell Transplant Shows Minimal OS, PFS Benefits in Patients With MM.
- Source :
-
American Journal of Managed Care . 2023 Supplement, p18-19. 2p. - Publication Year :
- 2023
-
Abstract
- The article discusses research that shows allogeneic stem cell transplant (allo-SCT) may not significantly benefit most patients with multiple myeloma. It considers the overall survival and progression-free survival after allo-SCT. The feasibility of alternatives such as CAR T-cell or bispecific T-cell engager therapies is suggested. The findings were presented at the 64th American Society of Hematology Annual Meeting and Exposition in New Orleans, Louisiana.
Details
- Language :
- English
- ISSN :
- 10880224
- Database :
- Academic Search Index
- Journal :
- American Journal of Managed Care
- Publication Type :
- Academic Journal
- Accession number :
- 161640294